MSFT · Investment summary · as of 12 August 2026
Priced close to what the business has demonstrated
Business type: Compounder · mature and structurally stable
At $492.45, MSFT requires a 9% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 18%.
Both axes solved: required CAGR 8.89% at 46.0% margin; required terminal margin 30.27% at +17.79% growth.
The value rests on an exit multiple of 22.6x, a terminal operating margin of 46% and a 9.3% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: AI-capex payback failure via the concentrated counterparty: OpenAI (roughly 40-45% of the $678bn commercial RPO, implied by +84% total vs +25% ex-OpenAI growth) fails to fund or perform its Azure commitments during CY2027 while Microsoft carries ~$175bn/yr capex, ~2/3 short-lived GPU/CPU assets whose depreciation arrives regardless.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | Both axes solved: required CAGR 8.89% at 46.0% margin; required terminal margin 30.27% at +17.79% growth. |
| What do we forecast? | Revenue growth of 18% demonstrated; a terminal operating margin of 46%; an exit multiple of 22.6x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is +8.9 percentage points. |
| What is it worth? | Twelve-month target $533.59, +8% from the struck price. Scenario-weighted expected return net of costs +4.1%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| each FY2027 quarter | The demand-exceeds-supply regime underpinning the +17.79%… | Azure revenue growth (constant currency) at or above 35% in any FY2027 quarter (guided ~45% for Q1 FY27 with H1… | Azure revenue growth (constant currency) below 35% in any FY2027 quarter (guided ~45% for Q1 FY27 with H1 accelerating). |
| each quarter | Commercial RPO ex-OpenAI growth below 20% y/y in any quarter… | Commercial RPO ex-OpenAI growth at or above 20% y/y in any quarter (currently +25%). | Commercial RPO ex-OpenAI growth below 20% y/y in any quarter (currently +25%). |
| each quarter, two consecutive | The AI-capacity cost drag staying inside the efficiency offset the… | Microsoft Cloud gross margin at or above 62% for two consecutive quarters (currently 65%, guided relatively stable q/q). | Microsoft Cloud gross margin below 62% for two consecutive quarters (currently 65%, guided relatively stable q/q). |
| quarterly and FY2027 close | The capex-does-not-eat-the-model claim; replaces the old 'FY27 capex… | Company operating margin below prior-year quarter by more than 1.5pp in two consecutive quarters, or FY2027 operating… | Company operating margin below prior-year quarter by more than 1.5pp in two consecutive quarters, or FY2027 operating… |
AI-capex payback failure via the concentrated counterparty: OpenAI (roughly 40-45% of the $678bn commercial RPO, implied by +84% total vs +25% ex-OpenAI growth) fails to fund or perform its Azure commitments during CY2027 while Microsoft carries ~$175bn/yr capex, ~2/3 short-lived GPU/CPU assets whose depreciation arrives regardless. Azure growth halves; operating margin compresses ~5pp; multiple de-rates to the 2022-23 trough of its own NTM series (16x).
Estimated probability 12%, against the 26% level at which the position would be resized. It sits within that level.
Falsifiable and fundamental — not one of them is a price condition.
On approach to $534 (base target) only if forward E[R] at that price (~0%) loses slot competition; not an automatic trim. On approach to the $533.59 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | AI-capex payback failure via the concentrated counterparty: OpenAI (roughly 40-45% of the $678bn commercial RPO, implied by +84% total vs +25% ex-OpenAI growth) fails to fund or perform its Azure commitments during CY2027 while Microsoft carries ~$175bn/yr capex, ~2/3 short-lived GPU/CPU assets whose depreciation arrives regardless. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +8.9 percentage points more growth than the price requires. The most important unresolved uncertainty is the permanent-loss mechanism: AI-capex payback failure via the concentrated counterparty: OpenAI (roughly 40-45% of the $678bn commercial RPO, implied by +84% total vs +25% ex-OpenAI growth) fails to fund or perform its Azure commitments during CY2027 while Microsoft carries ~$175bn/yr capex, ~2/3 short-lived GPU/CPU assets whose depreciation arrives regardless. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $433.36, which forces an immediate review.